Navigation Links
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Date:9/13/2007

First Patient Enrolled in Pivotal Studies

BETHESDA, Md., Sept. 13 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that the first patient has been enrolled in a Phase III study of lubiprostone (24 mcg, oral gel capsules, twice daily) for the treatment of Opioid-Induced Bowel Dysfunction (OBD). The OBD Pivotal Assessment of Lubiprostone (OPAL) program consists of two 12-week double-blind studies, followed by a nine-month open-label safety extension study. The double-blind studies are expected to enroll approximately 840 patients at up to 190 sites in the United States and Canada and will evaluate the effects of lubiprostone as a treatment for constipation stemming from the use of narcotic medications, such as morphine and codeine, prescribed for chronic pain management.

Lubiprostone, a chloride channel activator developed by Sucampo Pharmaceuticals, is currently approved for the treatment of Chronic Idiopathic Constipation in adults as AMITIZA(R) (24 mcg, oral gel capsules, twice daily) and is under FDA review for Irritable Bowel Syndrome with constipation. AMITIZA is marketed in the United States by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

"Each year, millions of patients who suffer from chronic pain are treated with opiates," said Egilius L. H. Spierings, M.D., Ph.D, Associate Clinical Professor of Neurology at Brigham and Women's Hospital, Harvard Medical School. "Many of these patients frequently develop severe constipation from these powerful analgesics; however, there are currently no approved prescription products available to treat this condition. This study is designed t
'/>"/>

SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... Gribbin of Clarksburg, president and CEO of CentraState Healthcare ... the board of the New Jersey Hospital Association (NJHA), ... well as the appointment of new board members, was ... Regency Princeton. "Here in our state, the enormous problems ...
... A French study reported in the 12th January issue ... a strong correlation between blood pressure and outdoor temperature ... result, the investigators advise that, during periods of extreme ... "could contribute to reducing the consequences of blood pressure ...
... at National Jewish Health and the University of Colorado Denver ... among patients with acute lung injury. Acute lung injury (ALI) ... low oxygen levels in the blood, and fluid in the ... intensive care units, afflicting almost 200,000 people in the United ...
... As the health insurance market increasingly becomes consumer-driven, BlueCross ... shopping for insurance with face-to-face assistance at the company,s ... 23 in Mount Pleasant, S.C.Located at 615 Johnnie Dodds ... Shopping Center, the 1,800 square foot SC BlueStore(SM) ...
... BEAVERTON, Ore., Jan. 16 Includesdental.com announces ... for dentists, hygienists and other oral health ... to search for product reviews, clinical research, ... across thousands of sites."With Includesdental.com, dentists can ...
... severity among female patients., , , FRIDAY, Jan. 16 (HealthDay ... often and more severely than men, new research suggests. ... from around the world who had RA, about 79 ... had poorer outcomes in key measures such as symptoms ...
Cached Medicine News:Health News:Hospital Association Names New Chairman, Appoints Board Officers and New Members 2Health News:Seasonal variation in blood pressure 2Health News:Gene associated with reduced mortality from acute lung injury 2Health News:S.C. BlueCross to Open Its First Health Insurance Retail Store 2Health News:Includesdental.com Announces Search Engine for Dentists, Hygienists and Oral Health Industry 2Health News:Rheumatoid Arthritis Hits Women Harder 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: